Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study

Aim Chemotherapy side effects are often reported in clinical trials; however, there is little evidence about their incidence in routine clinical care. The objective of this study was to describe the frequency and severity of patient-reported chemotherapy side effects in routine care across treatment centres in Australia. Methods We conducted a prospective cohort study of individuals with breast, lung or colorectal cancer undergoing chemotherapy. Side effects were identified by patient self-report. The frequency, prevalence and incidence rates of side effects were calculated by cancer type and grade, and cumulative incidence curves for each side effect computed. Frequencies of side effects were compared between demographic subgroups using chi-squared statistics. Results Side effect data were available for 449 eligible individuals, who had a median follow-up of 5.64 months. 86% of participants reported at least one side effect during the study period and 27% reported a grade IV side effect, most commonly fatigue or dyspnoea. Fatigue was the most common side effect overall (85%), followed by diarrhoea (74%) and constipation (74%). Prevalence and incidence rates were similar across side effects and cancer types. Age was the only demographic factor associated with the incidence of side effects, with older people less likely to report side effects. Conclusion This research has produced the first Australian estimates of self-reported incidence of chemotherapy side effects in routine clinical care. Chemotherapy side effects in routine care are common, continue throughout chemotherapy and can be serious. This work confirms the importance of observational data in providing clinical practice-relevant information to decision-makers.

[1]  R. Norman,et al.  Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study , 2015, Asia-Pacific journal of clinical oncology.

[2]  R. Viney,et al.  Can administrative data be used to measure chemotherapy side effects? , 2015, Expert review of pharmacoeconomics & outcomes research.

[3]  Gaetano Rocco,et al.  Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[5]  M. Schymura,et al.  Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer , 2012, Cancer.

[6]  M. Piccart,et al.  Long-term toxic effects of adjuvant chemotherapy in breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Halm,et al.  Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study , 2011, BMJ : British Medical Journal.

[8]  B. Eldadah.  Fatigue and Fatigability in Older Adults , 2010, PM & R : the journal of injury, function, and rehabilitation.

[9]  Robert H Fletcher,et al.  Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. , 2010, JAMA.

[10]  Paul Gallagher,et al.  Constipation in old age. , 2009, Best practice & research. Clinical gastroenterology.

[11]  Isabelle Boutron,et al.  Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.

[12]  Chiun-Sheng Huang,et al.  Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. , 2008, Breast.

[13]  David Cella,et al.  Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. , 2008, Supportive Care in Cancer.

[14]  L. Garrison,et al.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  M. Kris,et al.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. , 2006, The Lancet. Oncology.

[16]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Colevas,et al.  Adverse event reporting in publications compared with sponsor database for cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Avins,et al.  Brief Communication: Better Ways To Question Patients about Adverse Medical Events , 2006, Annals of Internal Medicine.

[19]  A. Sureda,et al.  Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. , 2006, Haematologica.

[20]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[21]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[22]  M. Mori,et al.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Eichler,et al.  The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Xianglin L. Du,et al.  Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  David Khayat,et al.  Changing patient perceptions of the side effects of cancer chemotherapy , 2002, Cancer.

[26]  M. Drummond.  Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[28]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[29]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[30]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[31]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.